TY - JOUR
T1 - Downregulation of T cell receptor expression by CD8+ lymphocytes in kidney allografts
AU - Mannon, Roslyn B.
AU - Kotzin, Brian L.
AU - Nataraj, Chandra
AU - Ferri, Karen
AU - Roper, Ellen
AU - Kurlander, Roger J.
AU - Coffman, Thomas M.
PY - 1998/6/1
Y1 - 1998/6/1
N2 - Allospecific CD8+ T lymphocytes are an important component of the cellular response in allograft rejection. These cells recognize and engage MHC class I antigens, leading to allospecific cytolytic responses and graft rejection. In mouse kidney allografts that survive to 3 wk after transplantation, we noted that the majority of CD8+ cells do not express surface α/β T cell receptor α/β(TCR), γ/δTCR, or CD3. However, these CD8+TCR- cells did express surface markers characteristic of T cells, including Thy1.2, CD2, and CD5. In addition, the CD8+TCR- cells expressed mRNA for TCR Vβ gene families, and nearly half stained positive for cytoplasmic Vβ8 protein, suggesting that they are T cells that have downregulated α/βTCR protein expression from their cell surfaces. When these surface TCR- cells were isolated from kidney allografts by flow cytometry and cultured in the presence of either allogeneic or syngeneic stimulators, nearly 100% of cells reacquired normal levels of α/βTCR expression with disproportionate usage of Vβ8 chains. After recovery of their surface TCR expression, the CD8+TCR- population demonstrated strong alloreactivity in culture. These results suggest that the substantial number of CD8+TCR- cells found in long-term surviving mouse kidney allografts are α/β-T cells that have downregulated their cell surface expression of TCR. While in other systems this phenotype may identify cells that have engaged antigen, our results indicate that loss of TCR expression by CD8+ kidney graft-infiltrating cells may not depend on antigen engagement and that elements in the microenvironment of the kidney graft play a key role in this process. Factors that modulate expression of TCR by graft-infiltrating lymphocytes may have an important role in regulating rejection responses.
AB - Allospecific CD8+ T lymphocytes are an important component of the cellular response in allograft rejection. These cells recognize and engage MHC class I antigens, leading to allospecific cytolytic responses and graft rejection. In mouse kidney allografts that survive to 3 wk after transplantation, we noted that the majority of CD8+ cells do not express surface α/β T cell receptor α/β(TCR), γ/δTCR, or CD3. However, these CD8+TCR- cells did express surface markers characteristic of T cells, including Thy1.2, CD2, and CD5. In addition, the CD8+TCR- cells expressed mRNA for TCR Vβ gene families, and nearly half stained positive for cytoplasmic Vβ8 protein, suggesting that they are T cells that have downregulated α/βTCR protein expression from their cell surfaces. When these surface TCR- cells were isolated from kidney allografts by flow cytometry and cultured in the presence of either allogeneic or syngeneic stimulators, nearly 100% of cells reacquired normal levels of α/βTCR expression with disproportionate usage of Vβ8 chains. After recovery of their surface TCR expression, the CD8+TCR- population demonstrated strong alloreactivity in culture. These results suggest that the substantial number of CD8+TCR- cells found in long-term surviving mouse kidney allografts are α/β-T cells that have downregulated their cell surface expression of TCR. While in other systems this phenotype may identify cells that have engaged antigen, our results indicate that loss of TCR expression by CD8+ kidney graft-infiltrating cells may not depend on antigen engagement and that elements in the microenvironment of the kidney graft play a key role in this process. Factors that modulate expression of TCR by graft-infiltrating lymphocytes may have an important role in regulating rejection responses.
KW - Kidney transplantation
KW - Minor histocompatibility antigens
KW - Rejection
KW - T cell receptor
KW - Transgenic mice
UR - http://www.scopus.com/inward/record.url?scp=0032103370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032103370&partnerID=8YFLogxK
U2 - 10.1172/JCI1229
DO - 10.1172/JCI1229
M3 - Article
C2 - 9616223
AN - SCOPUS:0032103370
SN - 0021-9738
VL - 101
SP - 2517
EP - 2527
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 11
ER -